Ribociclib

Ribociclib, also known as LEE011, is an investigational drug being studied in clinical trials for the treatment of several types of cancer. This article summarizes key information about ongoing clinical trials evaluating the efficacy and safety of ribociclib in conditions such as breast cancer, liposarcoma, glioblastoma, and other solid tumors.

Table of Contents

What is Ribociclib?

Ribociclib, also known by its brand name Kisqali® or research code LEE011, is a medication used primarily in the treatment of certain types of breast cancer[1]. It belongs to a class of drugs called CDK4/6 inhibitors, which work by blocking specific proteins involved in cell division[2].

How Ribociclib Works

Ribociclib works by inhibiting two important proteins in our cells called CDK4 and CDK6. These proteins play a crucial role in controlling how cells divide and grow. By blocking these proteins, ribociclib can help slow down or stop the growth of cancer cells[3].

The medication specifically targets a pathway in cells known as the Rb-E2F pathway. This pathway is often overactive in cancer cells, causing them to multiply rapidly. By interfering with this pathway, ribociclib can help control the spread of cancer[4].

Conditions Treated with Ribociclib

Ribociclib is primarily used to treat:

  • Breast Cancer: Specifically, it’s used for advanced or metastatic breast cancer that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-)[2]. This means the cancer cells have receptors for hormones like estrogen or progesterone, but don’t have too many HER2 proteins.
  • Liposarcoma: Some studies are investigating the use of ribociclib in treating well-differentiated or dedifferentiated liposarcoma, a type of soft tissue cancer[5].
  • Brain Tumors: Research is ongoing to evaluate the effectiveness of ribociclib in treating certain types of brain tumors, including glioblastoma and meningioma[4].

Dosage and Administration

Ribociclib is typically taken orally in the form of tablets. The dosage and schedule can vary depending on the specific condition being treated and individual patient factors. However, some common dosing regimens include:

  • 600 mg once daily for 21 days, followed by 7 days off treatment in 28-day cycles[2].
  • 400 mg or 600 mg once daily for 21 days, followed by 7 days off treatment in 28-day cycles[6].

It’s important to note that ribociclib is often used in combination with other medications, such as hormone therapies like fulvestrant or aromatase inhibitors[2].

Potential Side Effects

Like all medications, ribociclib can cause side effects. Some of the potential side effects include:

  • Decreased white blood cell count (neutropenia)
  • Nausea and vomiting
  • Fatigue
  • Diarrhea
  • Hair loss
  • Liver function abnormalities

Your healthcare team will monitor you closely for these side effects and may adjust your dosage or provide supportive care as needed[7].

Ongoing Research and Future Applications

Researchers are continually studying ribociclib to understand its full potential and explore new applications. Some areas of ongoing research include:

  • Early-stage Breast Cancer: Studies are investigating the use of ribociclib in combination with endocrine therapy for patients with early high-risk HR+HER2- breast cancer[6].
  • Brain Tumors: Researchers are exploring how well ribociclib can penetrate the blood-brain barrier and its effectiveness against certain brain tumors[4].
  • Combination Therapies: Various studies are looking at combining ribociclib with other medications to enhance its effectiveness or expand its use to other types of cancers[8].

As research continues, our understanding of ribociclib and its potential applications in cancer treatment will likely expand, potentially offering new hope for patients with various types of cancer.

Cancer Type Trial Phase Combination Therapy Key Outcomes Measured
Breast Cancer (HR+/HER2-) II, III Endocrine therapy Invasive disease-free survival, Overall survival
Liposarcoma II Single agent Progression-free survival, Response rate
Glioblastoma 0/II Single agent Tumor pharmacokinetics, Safety
Advanced Solid Tumors I, II Various combinations Safety, Pharmacokinetics, Tumor response

Ongoing Clinical Trials on Ribociclib

  • Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Portugal Spain
  • Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

    Not recruiting

    1 1 1
    Austria Belgium Bulgaria France Germany Hungary +6
  • Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany
  • Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    France Spain
  • Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

    Not recruiting

    1 1 1 1
    The Netherlands
  • Study for Patients with Advanced Cancer Continuing Ribociclib Treatment

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain
  • Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months – 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Czechia Denmark France Germany Hungary Italy +1
  • Study on Ribociclib, Alpelisib, and Letrozole for Adults with Advanced Hormone Receptor-Positive Breast Cancer

    Not recruiting

    1 1 1
    France Spain
  • Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

    Not recruiting

    1 1
    Investigated diseases:
    Belgium France Germany Italy
  • Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

    Not recruiting

    1 1 1 1
    Austria Belgium France Germany Hungary Ireland +4

Glossary

  • CDK4/6: Cyclin-dependent kinases 4 and 6, proteins involved in regulating cell division that are targeted by ribociclib
  • Hormone receptor-positive (HR+): Cancer cells that have receptors for estrogen or progesterone, making them potentially responsive to hormone therapies
  • HER2-negative (HER2-): Cancer cells that do not have high levels of the HER2 protein, which promotes cell growth
  • Liposarcoma: A rare type of cancer that develops in fat cells in soft tissues
  • Glioblastoma: An aggressive type of cancer that occurs in the brain or spinal cord
  • Meningioma: A tumor that forms on membranes covering the brain and spinal cord
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing
  • Overall survival (OS): The length of time from the start of treatment until death from any cause
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment

References

  1. https://clinicaltrials.gov/study/NCT02754011
  2. https://clinicaltrials.eu/trial/study-on-the-safety-and-antitumor-activity-of-arv-471-and-ribociclib-in-adults-with-er-advanced-or-metastatic-breast-cancer/
  3. https://clinicaltrials.gov/study/NCT02345824
  4. https://clinicaltrials.gov/study/NCT02933736
  5. https://clinicaltrials.gov/study/NCT02571829
  6. https://clinicaltrials.gov/study/NCT06587789
  7. https://clinicaltrials.gov/study/NCT05625087
  8. https://clinicaltrials.gov/study/NCT03090165